ANAPTYSBIO, INC. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
ANAPTYSBIO, INC. (ANAB) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $201.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2018-11-08
- 2018-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $201.00K.
- 2018-06-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $369.00K.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2018-09-30 | $201.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $369.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |